Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2
- 9 July 2009
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 219 (3), 294-305
- https://doi.org/10.1002/path.2603
Abstract
High-grade osteosarcoma is characterized by extensive genetic instability, thereby hampering the identification of causative gene mutations and understanding of the underlying pathological processes. It lacks a benign precursor lesion and reports on associations with hereditary predisposition or germline mutations are uncommon, despite the early age of onset. Here we demonstrate a novel comprehensive approach for the study of premalignant stages of osteosarcoma development in a murine mesenchymal stem cell (MSC) system that formed osteosarcomas upon grafting. By parallel functional and phenotypic analysis of normal MSCs, transformed MSCs and derived osteosarcoma cells, we provide substantial evidence for a MSC origin of osteosarcoma. In a stepwise approach, using COBRA–FISH karyotyping and array CGH in different passages of MSCs, we identified aneuploidization, translocations and homozygous loss of the cdkn2 region as the key mediators of MSC malignant transformation. We then identified CDKN2A/p16 protein expression in 88 osteosarcoma patients as a sensitive prognostic marker, thereby bridging the murine MSCs model to human osteosarcoma. Moreover, occasional reports in patients mention osteosarcoma formation following bone marrow transplantation for an unrelated malignancy. Our findings suggest a possible hazard for the clinical use of MSCs; however, they also offer new opportunities to study early genetic events in osteosarcoma genesis and, more importantly, to modulate these events and record the effect on tumour progression. This could be instrumental for the identification of novel therapeutic strategies, since the success of the current therapies has reached a plateau phase. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
Funding Information
- EuroBoNet
- Netherlands Organization for Health Research and Development (92003-399)
This publication has 38 references indexed in Scilit:
- Osteosarcoma Development and Stem Cell DifferentiationClinical Orthopaedics and Related Research, 2008
- Molecular Characterization of Spontaneous Mesenchymal Stem Cell TransformationPLOS ONE, 2008
- Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma IntergroupJNCI Journal of the National Cancer Institute, 2007
- Sarcoma Derived from Cultured Mesenchymal Stem CellsThe International Journal of Cell Cloning, 2006
- Spontaneous Human Adult Stem Cell TransformationCancer Research, 2005
- Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumorsCancer Genetics and Cytogenetics, 2003
- Etiology of OsteosarcomaClinical Orthopaedics and Related Research, 2002
- Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group ProtocolsJournal of Clinical Oncology, 2002
- Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocolEuropean Journal of Cancer, 2001
- Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicinCancer, 1993